Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Narendra I Gandhi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSEName of the Target Company (TC) : Lyka Labs LtdName of the Promoter(s) on whose shares encumbrance was created/ invoked/ released : Narendra I GandhiDate of reporting : November 17, 2011... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Kunal N Gandhi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSEName of the Target Company (TC) : Lyka Labs LtdName of the Promoter(s) on whose shares encumbrance was created/ invoked/ released : Kunal N GandhiDate of reporting : November 17, 2011... Updates to MOU for Transfer of Technical Know How / Technology
With reference to the earlier announcement dated December 17, 2011, Lyka Labs Ltd has now informed BSE that in the said announcement the Company have mentioned MOU entered with "European based Company" which shall be corrected as "Company based in Rupublic of Turkey" to manufacture lyophilized product for a consideration of US $ 2,50,000 and Royally for five years. MOU for Transfer of Technical Know How / Technology
Lyka Labs Ltd has informed BSE that the Company has entered MOU with European based Company for Transfer Known- How / Technology to manufacture lyophilized product for a consideration of US $ 2,50,000 and Royally for five years. Demise of Director
Lyka Labs Ltd has informed BSE that Shri. S S Upadhyaya - Director of the Company expired on November 08, 2011. Resignation of CFO
Lyka Labs Ltd has informed BSE that Shri. Manish Jayavant - Chief Finance Officer of the Company has resigned w.e.f. October 22, 2011. Financial Results for Sep 30, 2011
Lyka Labs Ltd has informed BSE about the Financial Results for the Period ended September 30, 2011. Disclosures under Reg. 8A(4) of SEBI (SAST) Regulations, 1997
Lyka Labs Ltd has now submitted the disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 1997 to BSEDate of Reporting : November 04, 2011Name of the Company : Lyka Labs LtdTotal no of outstanding shares of the Company : 21580000Name of the Entity : Narendra I GandhiDetails of Transaction... Patent Award
Lyka Labs Ltd has informed BSE that the Company has been conferred Certificate of Appreciation Patent Award for the year 2010 - 2011 by Pharmaceuticals Export Promotion Council in recognition of commendable contribution to R&D; in formulation sector. DCGI approval Glutathione Injection
Lyka Labs Ltd has informed BSE that the Company has received permission from Drugs Controller General (India) vide their letter dated September 14, 2011 to manufacture Glutathione for Injection. Glutathione Injection is used for the treatment of Alcoholic Liver Diseases such as:1. Alcoholic Fatty Liver2. Fibrosis3. Cirrhosis4. HepatitisLyka is the first Company in India to get the permission of Glutathione Injection.